HIMS Reiterates Buy Rating with $32 Price Target, 16% Upside
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Source: stocktwits
- Buy Rating Reaffirmed: Canaccord Genuity reiterated its 'Buy' rating on HIMS, maintaining a $32 price target that implies a 16% upside from current levels, reflecting market confidence in HIMS's future growth potential.
- Peptide Product Opportunity: As HIMS expands into preventive health and longevity, Canaccord sees peptides as a long-term growth driver, especially with the FDA reviewing several peptide substances, which could open new market opportunities for the company.
- Acquisition and Innovation: HIMS acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities, enhancing its domestic supply chain and supporting future innovations in areas like preventive health and metabolic optimization.
- Market Expansion Strategy: HIMS recently completed the acquisition of digital health platform Eucalyptus, aiming for $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, demonstrating its proactive approach to diversifying its business and expanding into international markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 31.890
Low
16.50
Averages
32.95
High
60.00
Current: 31.890
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Faces Key Regulatory Meeting on Peptides
- Regulatory Meeting Impact: The Pharmacy Compounding Advisory Committee is set to meet on July 23-24 to decide on adding seven peptides to the FDA's 503A Bulk List, a move that could serve as a catalyst for Hims' growth prospects beyond 2027.
- Market Performance Recovery: HIMS shares have surged over 20% recently, trading close to $31.8, breaking through the $30 resistance level from April, indicating optimistic market sentiment regarding future growth.
- Potential Revenue Expectations: FirstWave Fund CEO Jonah Lupton stated that if Hims captures 4% to 5% of the GLP and non-GLP peptide markets, annual revenues could reach between $10 billion and $19 billion by 2030, significantly enhancing the company's market position.
- Investor Focus: Despite the long-term opportunities presented by peptides, Leerink noted that investor attention is likely to remain on Hims' near-term growth and profitability trends in the GLP-1 business, especially following the company's recent acquisition of Eucalyptus, which has expanded its operations across multiple countries.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Momentum
- Growth Through Partnership: Novo Nordisk announced on March 9 that it will sell its blockbuster drugs Wegovy and Ozempic through Hims & Hers, with Barclays noting improved customer momentum, indicating a positive impact from the collaboration.
- Price Target Increase: Barclays raised its price target for Hims & Hers from $29 to $39, implying a 21% upside from the last closing price, reflecting increased confidence in the company's future growth trajectory.
- Revenue Acceleration Expectations: Revenue and EBITDA for Hims & Hers are expected to significantly accelerate in the second half of 2026 due to strong demand for weight-loss products and contributions from other business lines, further solidifying its market position.
- Market Sentiment Rebound: Retail sentiment for Hims & Hers improved from 'bullish' to 'extremely bullish', with message activity rising over 120% in the past week, indicating investor optimism regarding the company's outlook.
See More
Hims' Peptide Market Outlook for the Next Decade
- Massive Market Potential: Lupton projects that the global peptide market could generate between $250 billion and $380 billion in annual revenue by 2030, and if Hims captures 4%-5% market share, peptide revenue could reach $10 billion to $19 billion, indicating significant growth opportunities in this sector.
- Stock Price Surge: Shares of Hims & Hers Health, Inc. (HIMS) jumped over 12% on Monday to close at $30.17, marking the best performance in two months, reflecting growing market optimism surrounding peptide products.
- Regulatory Support: Canaccord Genuity reiterated a ‘Buy’ rating and a $32 price target for Hims, suggesting that peptides could emerge as a long-term growth driver, with FDA reviews potentially shifting demand from unregulated channels to mainstream healthcare platforms.
- Strategic Expansion: Hims has acquired a California-based peptide manufacturing facility to bolster its domestic supply chain and has expanded its vertically-integrated healthcare platform, demonstrating a strategic focus on metabolic health and cognitive performance, thereby strengthening its position in international markets.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Hims & Hers Stock Surges 12.49% Amid Obesity Market Optimism
- Stock Surge: Hims & Hers saw its stock price rise by 12.49% on Monday, closing at $30.17 per share, reflecting investor optimism regarding the company's growth prospects in the obesity market, indicating strong market confidence in its business model.
- Obesity Treatment Demand: Chief Medical Officer Craig Primack highlighted that approximately 64% of UK adults are overweight or living with obesity, and NHS specialist weight management services are overwhelmed, with waiting lists closed in multiple regions, illustrating the inability of traditional healthcare systems to meet the surging demand for obesity treatment.
- Integrated Treatment Solutions: Hims & Hers offers FDA-approved obesity and weight loss treatments, Wegovy and Ozempic, and aims to enhance treatment outcomes and patient satisfaction by integrating medication, nutritional coaching, and clinical support, effectively removing friction in the treatment process.
- Market Opportunity: Primack emphasized that closing the gap between the obesity epidemic and the capacity of traditional care systems requires clinical rigor and sustained support, positioning Hims & Hers to capture a larger market share and influence in the future.
See More
HIMS Shares Eye Breakout Above $30 Resistance Level
- Price Fluctuation: HIMS shares peaked at $29.97 on Monday before dipping to $29.70, indicating market anticipation for a breakout above the $30 to $32 resistance level, which could propel the stock towards $40 if successful.
- Retail Sentiment Shift: Retail investor sentiment on Stocktwits shifted from neutral to bullish, with message volumes surging over 90%, reflecting optimistic expectations for HIMS's future performance and further driving the stock price upward.
- New Product Pre-Orders: CEO Andrew Dudum announced that the recently acquired Juniper platform is opening pre-orders for Novo Nordisk's Wegovy pill in the UK, marking a significant expansion into the weight loss drug market, which is expected to boost sales.
- Strategic Acquisition: HIMS completed the acquisition of digital health platform Eucalyptus, further expanding its presence in the U.S., UK, Australia, and Canada, with plans to achieve $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, demonstrating confidence in long-term growth.
See More
Hims & Hers Faces Key Regulatory Meeting on Peptides
- Regulatory Meeting Impact: The Pharmacy Compounding Advisory Committee is set to meet on July 23-24 to decide on adding seven peptides to the FDA's 503A Bulk List, a move that could serve as a catalyst for Hims' growth prospects beyond 2027.
- Market Performance Recovery: HIMS shares have surged over 20% recently, trading close to $31.8, breaking through the $30 resistance level from April, indicating optimistic market sentiment regarding future growth.
- Potential Revenue Expectations: FirstWave Fund CEO Jonah Lupton stated that if Hims captures 4% to 5% of the GLP and non-GLP peptide markets, annual revenues could reach between $10 billion and $19 billion by 2030, significantly enhancing the company's market position.
- Investor Focus: Despite the long-term opportunities presented by peptides, Leerink noted that investor attention is likely to remain on Hims' near-term growth and profitability trends in the GLP-1 business, especially following the company's recent acquisition of Eucalyptus, which has expanded its operations across multiple countries.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Momentum
- Growth Through Partnership: Novo Nordisk announced on March 9 that it will sell its blockbuster drugs Wegovy and Ozempic through Hims & Hers, with Barclays noting improved customer momentum, indicating a positive impact from the collaboration.
- Price Target Increase: Barclays raised its price target for Hims & Hers from $29 to $39, implying a 21% upside from the last closing price, reflecting increased confidence in the company's future growth trajectory.
- Revenue Acceleration Expectations: Revenue and EBITDA for Hims & Hers are expected to significantly accelerate in the second half of 2026 due to strong demand for weight-loss products and contributions from other business lines, further solidifying its market position.
- Market Sentiment Rebound: Retail sentiment for Hims & Hers improved from 'bullish' to 'extremely bullish', with message activity rising over 120% in the past week, indicating investor optimism regarding the company's outlook.
See More
Hims' Peptide Market Outlook for the Next Decade
- Massive Market Potential: Lupton projects that the global peptide market could generate between $250 billion and $380 billion in annual revenue by 2030, and if Hims captures 4%-5% market share, peptide revenue could reach $10 billion to $19 billion, indicating significant growth opportunities in this sector.
- Stock Price Surge: Shares of Hims & Hers Health, Inc. (HIMS) jumped over 12% on Monday to close at $30.17, marking the best performance in two months, reflecting growing market optimism surrounding peptide products.
- Regulatory Support: Canaccord Genuity reiterated a ‘Buy’ rating and a $32 price target for Hims, suggesting that peptides could emerge as a long-term growth driver, with FDA reviews potentially shifting demand from unregulated channels to mainstream healthcare platforms.
- Strategic Expansion: Hims has acquired a California-based peptide manufacturing facility to bolster its domestic supply chain and has expanded its vertically-integrated healthcare platform, demonstrating a strategic focus on metabolic health and cognitive performance, thereby strengthening its position in international markets.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Hims & Hers Stock Surges 12.49% Amid Obesity Market Optimism
- Stock Surge: Hims & Hers saw its stock price rise by 12.49% on Monday, closing at $30.17 per share, reflecting investor optimism regarding the company's growth prospects in the obesity market, indicating strong market confidence in its business model.
- Obesity Treatment Demand: Chief Medical Officer Craig Primack highlighted that approximately 64% of UK adults are overweight or living with obesity, and NHS specialist weight management services are overwhelmed, with waiting lists closed in multiple regions, illustrating the inability of traditional healthcare systems to meet the surging demand for obesity treatment.
- Integrated Treatment Solutions: Hims & Hers offers FDA-approved obesity and weight loss treatments, Wegovy and Ozempic, and aims to enhance treatment outcomes and patient satisfaction by integrating medication, nutritional coaching, and clinical support, effectively removing friction in the treatment process.
- Market Opportunity: Primack emphasized that closing the gap between the obesity epidemic and the capacity of traditional care systems requires clinical rigor and sustained support, positioning Hims & Hers to capture a larger market share and influence in the future.
See More
HIMS Shares Eye Breakout Above $30 Resistance Level
- Price Fluctuation: HIMS shares peaked at $29.97 on Monday before dipping to $29.70, indicating market anticipation for a breakout above the $30 to $32 resistance level, which could propel the stock towards $40 if successful.
- Retail Sentiment Shift: Retail investor sentiment on Stocktwits shifted from neutral to bullish, with message volumes surging over 90%, reflecting optimistic expectations for HIMS's future performance and further driving the stock price upward.
- New Product Pre-Orders: CEO Andrew Dudum announced that the recently acquired Juniper platform is opening pre-orders for Novo Nordisk's Wegovy pill in the UK, marking a significant expansion into the weight loss drug market, which is expected to boost sales.
- Strategic Acquisition: HIMS completed the acquisition of digital health platform Eucalyptus, further expanding its presence in the U.S., UK, Australia, and Canada, with plans to achieve $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, demonstrating confidence in long-term growth.
See More
